



Evofem Biosciences to Report First Quarter 2021 Results and Provide Corporate Update on Thursday, May 6, 2021

SAN DIEGO, April 22, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the first quarter ended March 31, 2021 as follows:

Thursday, May 6, 2021

Date	Thursday, May 6, 2021
Time	4:30 p.m. ET (1:30 p.m. PT)
Webcast (live and archived)	www.evofem.com under "Investors"
Dial-in numbers	(866) 503-5561 (U.S. toll-free) or (253) 336-2965
Conference ID	1899453

The live webcast and related slide presentation can be accessed through the Investors section of its [website](#) or directly at <https://evofem.investorroom.com/2021Q1Results>. Please connect to the Company's website at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 15 minutes prior to the start of the call.

The webcast will be archived at <https://evofem.investorroom.com/2021Q1Results>. A telephone replay will be available for 24 hours after the call at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 1899453.

About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product, **Phexxi®** contraceptive vaginal gel, in the United States in September 2020. Evofem's lead product candidate, EVO100, is being evaluated for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, '**EVOGUARD**.' For more information, please visit evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact

Amy Raskopf

Evofem Biosciences, Inc.

araskopf@evofem.com

Mobile: (917) 673-5775

SOURCE Evofem Biosciences, Inc.